Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Product liability reform

This article was originally published in The Gray Sheet

Executive Summary

Compromise product liability agreement worked out between Senators Slade Gorton (R-Wash.) and John Rockefeller (D-W.Va.) "could be brought to the Senate floor in the near future and is expected to be signed by" President Clinton, the lawmakers say in a June 11 release. The bill would place a cap on punitive damages against small businesses (defined as having fewer than 25 employees and annual revenues of less than $5 mil.) of the lesser of two times compensatory damages or $250,000, provide for a two-year statute of limitations and mandate an 18-year statute of repose for durable workplace goods in which the plaintiff has received, or is eligible to receive, workers' compensation. Senate Majority Leader Trent Lott (R-Miss.) has not yet determined when the bill will be brought to the floor; such a move is not likely until debate on the tobacco bill (S 1415) has ended, Lott's staffers say

You may also be interested in...



CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel